Something to throw into the mix on our hold, the G
Post# of 148110
"The parties return to court in November. On Monday, another federal judge approved an agreement for Gilead to pay $246.75 million to customers to settle claims that it charged “exorbitant” prices for critical HIV drugs while limiting the ability of any generic treatment to come to the market in a "pay to delay" scheme."